Clinical trials: Irinotecan, completed
Metastatic Colorectal Cancer
Phase I Trial of Sorafenib + FOLFIRI In Metastatic Colorectal Cancer
The purpose of this study is to assess the safety, the maximum tolerated dose and the recommended dose for phase II studies of a chemotherapy-combination of sorafenib, irinotecan, and 5-fluorouracil (5-FU)/folinic acid (FA)…
- Trial name
- NCT00780169
- Testing
- sorafenib + FOLFIRI
- Where
- Canada
- Volunteers
- 16 people
- Sponsor
- Ottawa Hospital Research Institute
Metastatic Colorectal Cancer
Irinotecan, Cetuximab and Everolimus to Patients With Metastatic Colorectal Cancer
This is an open, multicenter phase II trial of therapy with a combination of cetuximab, and irinotecan every second week combined with a daily dose of everolimus to patients with metastatic colorectal cancer with Kirsten rat…
- Trial name
- ICE (NCT01387880)
- Testing
- Everolimus
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- Herlev Hospital
Cancer
Study of Irinotecan on a Weekly Schedule in Children
The medicine being offered in this study is called Irinotecan. Irinotecan has been effective against many animal cancers. It has been given to both adults and children.
- Trial name
- NCT00062842
- Testing
- Irinotecan
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Baylor College of Medicine
Metastatic Colorectal Cancer
Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC)
Based on the results from preclinical study, the investigators suggest that the addition of simvastatin at a dose of cardiovascular use (40 ~ 80 mg qd daily) may overcome cetuximab resistance in KRAS mutant colorectal cancer via…
- Trial name
- NCT01281761
- Testing
- cetuximab/irinotecan/simvastatin
- Where
- South Korea
- Volunteers
- 52 people
- Sponsor
- Samsung Medical Center
Sarcoma
Irinotecan (Camptosar) in Patients With Advanced Sarcomas
Primary Objectives: 1. To determine the efficacy of the topoisomerase I (topo I) inhibitor irinotecan, delivered via a low-dose protracted schedule to patients with advanced sarcoma. 2.
- Trial name
- NCT00509860
- Testing
- Irinotecan
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- M.D. Anderson Cancer Center
Anal Cancer, Carcinoma of the Appendix
Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan, fluorouracil, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Anal Cancer, Carcinoma of the Appendix, Colorectal Cancer, Esophageal Cancer
- Trial name
- NCT00654160
- Testing
- fluorouracil, irinotecan hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Mayo Clinic
Metastatic Colorectal Cancer
A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer
This is an open-label, multicenter, phase 1 study of BBI608 in combination with FOLFIRI + Bavacizumab. This study population is adult Japanese patients with metastatic colorectal cancers in FOLFIRI + Bevacizumab combination…
- Trial name
- NCT02641873
- Testing
- BBI608, 5-FU, Irinotecan
- Where
- 2 sites in Japan
- Volunteers
- 4 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
Brain and Central Nervous System Tumors
Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00268359
- Testing
- bevacizumab, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Duke University
Metastatic Colorectal Cancer (mCRC)
Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients
This is a multicenter, open label, randomized bioequivalence study of BEVZ92 (bevacizumab biosimilar) and Avastin® with 2 parallel arms to compare the pharmacokinetic (PK) profile of BEVZ92 and Avastin® in combination with FOLFOX…
- Trial name
- NCT02069704
- Testing
- Bevacizumab biosimilar (BEVZ92), Avastin® (bevacizumab, reference product)
- Where
- 18 sites in Argentina, Brazil and 3 more
- Volunteers
- 142 people
- Sponsor
- mAbxience Research S.L.
Metastatic Colorectal Cancer
Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI.
The study is designed to analyze the pathological tumor response on resected colorectal cancer metastases after preoperative treatment with bevacizumab combined with FOLFOX or FOLFIRI regimen in a prospective cohort and to…
- Trial name
- BEV-ONCO2012 (NCT01858649)
- Testing
- Metastases resection, Bevacizumab, 5 FU
- Where
- 11 sites in Belgium
- Volunteers
- 60 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Colorectal Neoplasms, Neoplasm Metastasis
A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRC
The primary purpose of this study is to determine the non-inferiority of overall survival XELIRI with or without Bevacizumab compared with FOLFIRI with or without Bevacizumab as Second-line therapy in Patient with Metastatic…
- Conditions
- Colorectal Neoplasms, Neoplasm Metastasis, Intestinal Neoplasms, Gastrointestinal Neoplasms
- Trial name
- AXEPT (NCT01996306)
- Testing
- Bevacizumab, CPT-11 (Irinotecan), 5-FU Bolus
- Where
- Japan
- Volunteers
- 650 people
- Sponsor
- Epidemiological and Clinical Research Information Network
Solid Tumors
A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI
The purpose of this study is to assess the effect of concomitant ramucirumab (IMC-1121B) on the pharmacokinetics of irinotecan and its metabolite SN-38 when coadministered with folinic acid and 5-fluorouracil, in participants…
- Trial name
- NCT01634555
- Testing
- Ramucirumab (IMC-1121B), Irinotecan, Folinic acid
- Where
- 5 sites in United States
- Volunteers
- 29 people
- Sponsor
- Eli Lilly and Company
Breast Cancer
Irinotecan in Treating Patients With Metastatic or Recurrent Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have metastatic or…
- Trial name
- NCT00004182
- Testing
- irinotecan hydrochloride
- Where
- 2 sites in United States
- Sponsor
- Northwestern University
Colorectal Cancer, Metastasis
Phase II Study of Simvastatin Plus Irinotecan, Fluorouracil, and Leucovorin(FOLFIRI) for Metastatic CRC
This trial is designed to assess the tolerability and efficacy of simvastatin plus FOLFIRI (irinotecan, 5-FU, leucovorin) in metastatic colorectal cancer patients.
- Trial name
- NCT00313859
- Testing
- simvastatin
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Samsung Medical Center
Metastatic Colorectal Cancer
Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based Regimen
The purpose of this study is to assess the efficacy and safety of treatment with FOLFIRI-aflibercept compared to initial treatment with FOLFIRI-aflibercept (for 6 cycles) followed by maintenance with 5FU-aflibercept, in an…
- Trial name
- AFEMA (NCT03279289)
- Testing
- Aflibercept, Irinotecan, folinic acid (dl racemic)
- Where
- Spain
- Volunteers
- 170 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Advanced Solid Malignancies
Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid Malignancies (Oratecan-102)
The main objective of this study is to determine the maximum tolerated dose (MTD) of OratecanTM. Eligible subjects of this study are patients with histologically or cytologically confirmed malignant solid tumor refractory to…
- Trial name
- NCT00986843
- Testing
- HM30181AK tablet + Irinotecan tablets
- Where
- South Korea
- Volunteers
- 14 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Small Cell Lung Cancer
Irinotecan/Cisplatin Plus Simvastatin in Extensive Disease-Small Cell Lung Cancer (ED-SCLC)
3-Hydroxy-3-methylglutaryl CoA reductase inhibitors, commonly referred to as the statins, have proven therapeutic and preventative effects in cardiovascular diseases.
- Trial name
- NCT00452634
- Testing
- Irinotecan, Cisplatin, Simvastatin
- Where
- South Korea
- Volunteers
- 62 people
- Sponsor
- National Cancer Center, Korea
Metastatic Colorectal Cancer
Study of IMMU-130 in Patients With Relapsed/Refractory Colorectal Cancer
This is a Phase I trial to study the safety of IMMU-130. IMMU-130 is composed of a drug attached to an antibody. The drug is the active ingredient in irinotecan which is a common chemotherapy drug used for colorectal cancer.
- Trial name
- NCT01270698
- Testing
- IMMU-130
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Gilead Sciences
Rectal Cancer
A Study of Neoadjuvant Chemoradiotherapy With 5-FU/Leucovorin (FL) vs. TS-1/Irinotecan in Patients With Locally Advanced Rectal Cancer
This is an open-label, randomized phase II study. Patients will be randomly assigned to either FL or TS-1/irinotecan preoperative chemotherapy regimens by stratification.
- Trial name
- NCT01269216
- Testing
- 5-FU with leucovorin, TS-1 with Irinotecan
- Where
- South Korea
- Volunteers
- 136 people
- Sponsor
- Yonsei University
Esophageal Carcinoma, Esophagogastric Junction Carcinoma
Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)
In this study, participants with advanced or metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or Siewert type I adenocarcinoma of the esophagogastric junction (EGJ) that had progressed after first-line…
- Trial name
- NCT02564263
- Testing
- pembrolizumab, paclitaxel, docetaxel
- Volunteers
- 628 people
- Sponsor
- Merck Sharp & Dohme LLC